GlobeNewswire Inc | Sep 2, 2020 07:00AM EDT

September 02, 2020

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced todaythat it will present at two upcoming investor conferences in September:

Citis 15th Annual BioPharma Virtual ConferenceDate: Wednesday, September 9, 2020Time: 4:15 5:00 p.m. ET

Baird 2020 Global Healthcare ConferenceDate: Thursday, September 10, 2020Time: 2:35 3:05 p.m. ET

Webcast information for these events will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

AboutApplied TherapeuticsApplied Therapeuticsis a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companys lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial inJune 2019, read out positive top-line biomarker data in adult Galactosemia patients inJanuary 2020and announced full data from the trial inApril 2020. A pediatric Galactosemia study commenced inJune 2020and is currently ongoing. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM inSeptember 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

Investors:Maeve Conneighton (212) 600-1902 or appliedtherapeutics@argotpartners.com

Media:Gleb Sagitovmedia@appliedtherapeutics.com